Pramiracetam
Investigational racetam studied in small, older human trials. It is not an approved cognitive enhancer, and evidence from experimental amnesia or selected head-injury populations does not establish benefit for healthy users.
Pharmacokinetic model
A route-level PK model for pramiracetam is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Investigational Nootropic
- Suggested cadence
- once daily
Research behind this entry
-
Pharmacokinetics of oral pramiracetam in normal volunteers
Twelve healthy men received randomized single oral doses from 400 to 1600 mg. Exposure rose approximately linearly, Tmax was two to three hours, and reported elimination half-life ranged from 4.5 to 6.5 hours; the small…
-
Pramiracetam effects on scopolamine-induced amnesia in healthy volunteers
Two groups of 12 men received pramiracetam or placebo before an experimental scopolamine challenge. Partial attenuation of selected memory effects in this induced-amnesia design does not establish routine cognitive…
2 published studies referenced in the app, each with a plain-language summary.